Document is current

Article History

Received: 10 May 2017

Accepted: 8 December 2017

First Online: 17 January 2018

Ethics approval and consent to participate

: The research would be considered exempt under applicable federal regulations (45 CFR 46.101b) based on the American Association for Public Opinion Research policy participant category. Our respondents were active participants in that they opted-in to participate in the research based on their choice to continue from the screener to the survey. Moreover, our respondents were informed that their participation “gives you an opportunity to share your experiences when being diagnosed with PF”.

: Not applicable.

: GPC has served as an investigator or collaborator in industry-sponsored clinical trials (Boehringer Ingelheim, Bristol Myers Squibb, Fibrogen, Genentech, Gilead Sciences, Global Blood Therapeutics, and Intermune) and as an advisor to Boehringer Ingelheim, InterMune, Genentech, and Global Blood Therapeutics; he currently serves as the Chief Medical Officer of the Pulmonary Fibrosis Foundation. PB is an employee of Veracyte. SD reports no competing interests. DJL served as a consultant for Boehringer Ingelheim, Genentech, Gilead Sciences, Galapagos, Patara, Phillips Respironics, the Pulmonary Fibrosis Foundation, and Veracyte, and has received institutional research grants from Bayer, Boehringer Ingelheim, Fibrogen, Gilead Sciences, and Global Blood Therapeutics.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.